Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (10): 979-983.DOI: 10.3969/j.issn.1673-8640.2022.010.014
Previous Articles Next Articles
LI Mingwu, WANG Qinzhi(), SUN Farui
Received:
2021-03-05
Revised:
2022-04-07
Online:
2022-10-30
Published:
2022-11-14
Contact:
WANG Qinzhi
LI Mingwu, WANG Qinzhi, SUN Farui. Influence of MUC16 on the cell proliferation and invasion of osteosarcoma cells[J]. Laboratory Medicine, 2022, 37(10): 979-983.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.010.014
组别 | 培养12 h | 培养24 h | 培养48 h | 培养72 h | 培养96 h |
---|---|---|---|---|---|
sh-MUC16组 | 0.15±0.06 | 0.20±0.07*# | 0.25±0.07*# | 0.36±0.08*# | 0.50±0.05*# |
sh-Control组 | 0.18±0.05 | 0.34±0.07 | 0.39±0.03 | 0.57±0.04 | 0.75±0.07 |
空白组 | 0.15±0.03 | 0.35±0.11 | 0.42±0.12 | 0.63±0.10 | 0.73±0.05 |
F值 | 0.873 | 6.170 | 5.087 | 19.958 | 35.958 |
P值 | 0.438 | 0.011 | 0.021 | <0.001 | <0.001 |
组别 | 培养12 h | 培养24 h | 培养48 h | 培养72 h | 培养96 h |
---|---|---|---|---|---|
sh-MUC16组 | 0.15±0.06 | 0.20±0.07*# | 0.25±0.07*# | 0.36±0.08*# | 0.50±0.05*# |
sh-Control组 | 0.18±0.05 | 0.34±0.07 | 0.39±0.03 | 0.57±0.04 | 0.75±0.07 |
空白组 | 0.15±0.03 | 0.35±0.11 | 0.42±0.12 | 0.63±0.10 | 0.73±0.05 |
F值 | 0.873 | 6.170 | 5.087 | 19.958 | 35.958 |
P值 | 0.438 | 0.011 | 0.021 | <0.001 | <0.001 |
组别 | 迁移细胞数/ (个/高倍镜视野) | 侵袭细胞数/ (个/高倍镜视野) |
---|---|---|
sh-MUC16组 | 108.83±7.57 | 93.50±9.29 |
sh-Control组 | 131.33±11.20* | 122.25±7.78* |
空白组 | 127.83±9.22* | 127.00±9.92* |
F值 | 9.853 | 26.034 |
P值 | 0.002 | <0.001 |
组别 | 迁移细胞数/ (个/高倍镜视野) | 侵袭细胞数/ (个/高倍镜视野) |
---|---|---|
sh-MUC16组 | 108.83±7.57 | 93.50±9.29 |
sh-Control组 | 131.33±11.20* | 122.25±7.78* |
空白组 | 127.83±9.22* | 127.00±9.92* |
F值 | 9.853 | 26.034 |
P值 | 0.002 | <0.001 |
组别 | MUC16 | E-Cad | N-Cad |
---|---|---|---|
sh-MUC16组 | 0.21±0.05 | 0.65±0.05 | 0.27±0.12 |
sh-Control组 | 0.72±0.11* | 0.23±0.09* | 0.86±0.05* |
空白组 | 0.76±0.16* | 0.28±0.04* | 0.79±0.04* |
F值 | 42.627 | 76.559 | 105.144 |
P值 | <0.001 | <0.001 | <0.001 |
组别 | MUC16 | E-Cad | N-Cad |
---|---|---|---|
sh-MUC16组 | 0.21±0.05 | 0.65±0.05 | 0.27±0.12 |
sh-Control组 | 0.72±0.11* | 0.23±0.09* | 0.86±0.05* |
空白组 | 0.76±0.16* | 0.28±0.04* | 0.79±0.04* |
F值 | 42.627 | 76.559 | 105.144 |
P值 | <0.001 | <0.001 | <0.001 |
[1] | TIAN Z, GU Z, WANG X, et al. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy:an observational study[J]. Medicine(Baltimore), 2019, 98(19):e15650. |
[2] |
WANG C, JING J, CHENG L. Emerging roles of non-coding RNAs in the pathogenesis,diagnosis and prognosis of osteosarcoma[J]. Invest New Drugs, 2018, 36(6):1116-1132.
DOI URL |
[3] |
AITHAL A, RAUTH S, KSHIRSAGAR P, et al. MUC16 as a novel target for cancer therapy[J]. Expert Opin Ther Targets, 2018, 22(8):675-686.
DOI URL |
[4] |
COELHO R, MARCOS-SILVA L, RICARDO S, et al. Peritoneal dissemination of ovarian cancer:role of MUC16-mesothelin interaction and implications for treatment[J]. Expert Rev Anticancer Ther, 2018, 18(2):177-186.
DOI URL |
[5] | 刘畅, 张珉, 田兴. MUC16对胆囊癌细胞生物学行为的调控作用及机制分析[J]. 肿瘤学杂志, 2019, 25(5):436-441. |
[6] | HU J, SUN J. MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment[J]. Oncoimmunology, 2018, 7(10):e1487914. |
[7] |
CHEN Y, HUANG Y, KANWAL M, et al. MUC16 in non-small cell lung cancer patients affected by familial lung cancer and indoor air pollution:clinical characteristics and cell behaviors[J]. Transl Lung Cancer Res, 2019, 8(4):476-488.
DOI URL |
[8] | 刘江川, 黄海讯, 江洋, 等. 大黄酸通过抑制STAT3基因的表达调控骨肉瘤细胞的增殖和凋亡[J]. 现代肿瘤医学, 2020, 28(10):1624-1629. |
[9] |
MULAY K, MENON V, LAHANE S, et al. Endocrine mucin-producing sweat gland carcinoma(EMPSGC) of the eyelid:clinicopathologic features,immunohistochemical findings and review of literature[J]. Indian J Ophthalmol, 2019, 67(8):1374-1377.
DOI URL |
[10] | 陈昕, 汪希鹏. MUC16在卵巢癌发生发展中的研究进展[J]. 国际妇产科学杂志, 2016, 43(5):506-509. |
[11] | 陈永胜, 贾小婷. MUC16促进肺腺癌细胞侵袭转移[J]. 中国社区医师, 2019, 35(22):8-9. |
[12] | CRAWFORD A, HABER L, KELLY M P, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer[J]. Sci Transl Med, 2019, 11(497):eaau7534. |
[13] |
REYNOLDS I S, FICHTNER M, MCNAMARA D A, et al. Mucin glycoproteins block apoptosis;promote invasion,proliferation,and migration;and cause chemoresistance through diverse pathways in epithelial cancers[J]. Cancer Metastasis Rev, 2019, 38(1-2):237-257.
DOI URL |
[14] |
KANWAL M, DING X J, SONG X, et al. MUC16 overexpression induced by gene mutations promotes lung cancer cell growth and invasion[J]. Oncotarget, 2018, 9(15):12226-12239.
DOI PMID |
[15] |
SHEN H, GUO M, WANG L, et al. MUC16 facilitates cervical cancer progression via JAK2/STAT3 phosphorylation-mediated cyclooxygenase-2 expression[J]. Genes Genomics, 2020, 42(2):127-133.
DOI URL |
[16] | 李新, 田蜜, 彭冰, 等. 黏蛋白16基因通过磷酸肌醇3-激酶/蛋白激酶B通路调节胆囊癌细胞活力和迁移[J]. 解剖学报, 2019, 50(5):613-619. |
[17] |
LIU Q, CHENG Z, LUO L, et al. C-terminus of MUC16 activates Wnt signaling pathway through its interaction with β-catenin to promote tumorigenesis and metastasis[J]. Oncotarget, 2016, 7(24):36800-36813.
DOI PMID |
[18] | 陈敬腾, 余铃, 方硕, 等. Notch信号通路可通过激活Slug调控骨肉瘤上皮-间质转化[J]. 肿瘤防治研究, 2020, 47(1):6-12. |
[19] | 陈佳, 金炜, 胡晓波. 外泌体在消化道肿瘤转移中的研究进展[J]. 检验医学, 2020, 35(12):1220-1223. |
[1] | WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817. |
[2] | YANG Yuqiang, QUAN Xiaoli, WANG Liuyu, XIAN Wenfeng, YANG Hong. Expression of RRBP1 in osteosarcoma tissues and its effect on cell biological characteristics [J]. Laboratory Medicine, 2023, 38(9): 842-848. |
[3] | PAN Xin, LÜ Ying, LI Yang, LI Rongguo. Effects of miR-24-3p targeting CHD5 on migration,invasion and radiosensitivity of thyroid cancer cells [J]. Laboratory Medicine, 2023, 38(7): 640-646. |
[4] | ZHANG Yinlong, YANG Hong. Expression of long non-coding RNA ZFAS1 in osteosarcoma tissues [J]. Laboratory Medicine, 2023, 38(3): 240-244. |
[5] | BAI Wei, WANG Bin, GUO Jiarui, ZHU Guangpu, ZHU Liyan. Expression of PBX1 in osteosarcoma tissues and its influence on prognosis [J]. Laboratory Medicine, 2023, 38(10): 926-929. |
[6] | SHANG Zhenjun, WEI Wei, LIU Ruihan. Effect of inhibiting PTBP1 on the proliferation and invasiveness of choroidal melanoma cells [J]. Laboratory Medicine, 2023, 38(1): 51-55. |
[7] | SUN Xiaodan, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Research progress on the role of estrogen receptor in osteosarcoma [J]. Laboratory Medicine, 2022, 37(4): 313-318. |
[8] | SUN Xiaodan, XU Jing, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Inhibitory effects of antiestrogen on the proliferation and CCL2 expression of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(4): 319-324. |
[9] | HUAN Yu, CAI Xushan, JIAO Jiajun, WU Junlu, QUAN Wenqiang, ZHANG Chunli, XI Fang. Expression of Beclin 1 in breast invasive ductal carcinoma and its relationship with Ki67 [J]. Laboratory Medicine, 2019, 34(7): 595-599. |
[10] | JIANG Xiaohua, WEI Yu, SUN Jianwen, REN Konghua, CUI Beinian, WANG Wei, CHENG Yi. Correlation of AS160 phosphorylation with tumor cell proliferative activity in primary breast cancer [J]. Laboratory Medicine, 2016, 31(3): 220-223. |
[11] | CHEN Jing, SUN Fenyong, MA Ji.. Research on the function of miRNA-195 on bladder cancer cell [J]. , 2014, 29(5): 540-544. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||